In the last trading session, 1.87 million Capricor Therapeutics Inc (NASDAQ:CAPR) shares changed hands as the company’s beta touched 4.12. With the company’s per share price at $15.80 changed hands at $1.35 or 9.34% during last session, the market valuation stood at $718.42M. CAPR’s last price was a discount, traded about -48.1% off its 52-week high of $23.40. The share price had its 52-week low at $3.52, which suggests the last value was 77.72% up since then.
Analysts gave the Capricor Therapeutics Inc (CAPR) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CAPR as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Capricor Therapeutics Inc’s EPS for the current quarter is expected to be -0.09.
Capricor Therapeutics Inc (NASDAQ:CAPR) trade information
Instantly CAPR was in green as seen at the end of in last trading. With action 5.90%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 14.49%, with the 5-day performance at 5.90% in the green. However, in the 30-day time frame, Capricor Therapeutics Inc (NASDAQ:CAPR) is 6.76% up.
The consensus price target for the stock as assigned by Wall Street analysts is 15, meaning bulls need a downside of -5.33% from its current market value. According to analyst projections, CAPR’s forecast low is 10 with 21.5 as the target high. To hit the forecast high, the stock’s price needs a -36.08% plunge from its current level, while the stock would need to tank 36.71% for it to hit the projected low.
Capricor Therapeutics Inc (CAPR) estimates and forecasts
Year-over-year growth is forecast to reach -16.70% down from the last financial year.
Consensus estimates given by 7 financial analysts project the company’s revenue in the current quarter to hit an average of 9.87M. 3 analysts are of the opinion that Capricor Therapeutics Inc’s revenue for the current quarter will be 2.17M. The company’s revenue for the corresponding quarters a year ago was 12.09M and 4.91M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -18.35%. The estimates for the next quarter sales put growth at -55.84%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 30.59%. The 2025 estimates are for Capricor Therapeutics Inc earnings to decrease by -43.37%.
CAPR Dividends
Capricor Therapeutics Inc is expected to release its next quarterly earnings report in March.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 4.9401% or 1.55 million shares worth $7.39 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . With 872.18 shares estimated at $13.78 million under it, the former controlled 1.92% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 1.59% of the shares, roughly 721.99 shares worth around $11.41 million.
